That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

Musk has argued in favor of regulating AI. But venture capitalists like Andreessen, who founded Andreessen Horowitz, a VC ...

"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...